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TABLE 2
Scoring of Systemic Features in the
Marfan Syndrome*
Feature Points
Wrist and thumb sign 3
Wrist or thumb sign 1
Pectus carinatum deformity 2
Pectus excavatum or chest asymmetry 1
Hindfoot deformity 2
Plain pes planus 1
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2399Marfan syndrome, an autosomal dominant disorder of
connective tissue with an estimated prevalence of 1 in
5,000 to 10,000, is caused by abnormal ﬁbrillin-1 attrib-
utable to mutations in the FBN1 gene (2). Manifestations
involve multiple organ systems, including the aorta, heart
and valves, skeleton, eye, lungs, and dura. FBN1mutations
can be identiﬁed in the vast majority of patients satisfying
the revised Ghent criteria for Marfan syndrome (2). The
diagnosis of Marfan syndrome is made by use of clinical
criteria, imaging, family history, and genetic testing as
outlined in the revised Ghent criteria (Tables 1 and 2) (2).
Cardiovascular features of Marfan syndrome include
mitral valve prolapse, mitral regurgitation, aortic root
dilatation (most pronounced at the sinuses of Valsalva),
and aortic dissection (2). The descending aorta, although
less commonly involved in young patients, is also at risk
for aneurysm formation and dissection.
Other genetically triggered aortic aneurysm syndromes
and conditions associated with aortopathy may increase
the risk of aortic dissection in competitive athletes.
Loeys-Dietz syndrome is caused by mutations in TGFBR1
and TGFBR2 and is characterized by craniofacial features,
arterial tortuosity, and aneurysms of the aorta and branch
vessels, as well as increased risk of dissection at relatively
small arterial dimensions (3). Vascular Ehlers-Danlos
syndrome, caused by mutations in COL3A1, is associated
with dissection and rupture of the aorta and branch
vessels, even at relatively normal arterial dimensions.
TAA or dissection may be familial and is inherited as
an autosomal dominant trait with decreased penetrance
and variable expression. Mutations in several genes
have been recognized as causing TAA disease, including
ACTA2, TGFBR1, TGFBR2, FBN1, MYH11, SMAD3, MLCK,
and TGFB2. Familial TAA syndromes may be associated
with cerebral aneurysms or BAV; some patients have
nonvascular manifestations (4,5).
BAV, which affects w1% of the general population,
may be associated with dilatation of the aortic root orTABLE 1
Revised Ghent Criteria for the Diagnosis of
Marfan Syndrome
In the absence of a family history of Marfan syndrome, any of the following:
1. Dilated aorta (z score >2) and ectopia lentis ¼ Marfan syndrome*
2. Dilated aorta (z score >2) and FBN1 mutation ¼ Marfan syndrome
3. Dilated aorta (z score >2) and systemic score >7 (see Table 2) ¼
Marfan syndrome*
4. Ectopia lentis and FBN1 associated with known aortic dilatation ¼
Marfan syndrome
In the presence of a family history of Marfan syndrome, any of the following:
5. Ectopia lentis and family history of Marfan syndrome ¼ Marfan syndrome
6. Systemic score >7 and family history of Marfan syndrome ¼
Marfan syndrome*
7. Dilated aorta (z score >2 at age $20 y; z score >3 at <20 y of age)
and family history of Marfan syndrome ¼ Marfan syndrome*
*Caveat: Without discriminating features of another connective tissue disorder such as
Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, or Shprintzen-Goldberg syn-
drome,andaftermutationanalysis forTGFBR1,TGFBR2,TGFB2,SMAD3,SKI,COL3A1,orother
genes as appropriate. Other genes/conditions will emerge with time. Modiﬁed with permis-
sion from Loeys et al. (2) Copyright ª 2010, British Medical Journal Publishing Group.ascending aorta (6). BAV with or without TAA may be
familial, and the speciﬁc gene loci responsible are yet to
be determined. The prevalence of BAV in ﬁrst-degree
relatives of a person with BAV has been demonstrated to
be w9% (6). Cystic medial degeneration and abnormal
aortic wall stress accompany BAV aortic disease inde-
pendent of the valvular lesion (6). BAV with aortic aneu-
rysm is a risk factor for aortic dissection (7). The risk
of aortic dissection differs among genetically triggered
aortopathies, being higher in those with Loeys-Dietz
syndrome and Marfan syndrome than in BAV aortopathy.
MEASURING THE AORTIC ROOT AND
ASCENDING AORTA
The ascending aorta may be divided into 2 segments, the
aortic root and the upper ascending aorta. The aortic root
begins at the aortic valve, includes the sinuses of Val-
salva, and extends to the sinotubular junction. The upper
portion of the ascending aorta begins at the sinotubular
junction and rises to join the aortic arch. The normal
aortic root diameter is dependent on multiple factors,
including age, sex, body size, location of the aortic mea-
surement, particular type of imaging modality used, and
accuracy of measurement ascertainment (4,8). In adults,
aortic diameters are larger in men than in women by 1 to 3
mm, whereas studies in children have not consistentlyPneumothorax 2
Lumbosacral dural ectasia 2
Protrusio acetabuli 2
Reduced upper-segment to lower-segment ratio (<0.85 in white
adults; <0.78 in black adults) and increased arm span–to-height
ratio (>1.05) and no severe scoliosis
1
Scoliosis or thoracolumbar kyphosis 1
Reduced elbow extension 1
Facial features (3 of 5): dolichocephaly, enophthalmos, down-slanting
palpebral ﬁssures, malar hypoplasia, retrognathia
1
Skin striae 1
Myopia (>3 diopters) 1
Mitral valve prolapse 1
Maximum total, 20 points; score >7 indicates systemic involvement.
*A detailed explanation of the systemic score and nosology may be found at
http://www.marfandx.org.
Modiﬁed with permission from Loeys et al. (2) Copyright ª 2010, British Medical
Journal Publishing Group.
FIGURE Schematic of the Aortic Root Showing Measurement of
the Aortic Root Diameter at Maximum Width Parallel to the
Aortic Annular Plane by American Society of Echocardiography
Leading-Edge Convention (Arrows)
AO indicates aorta; LA, left atrium; and LV, left ventricle. Reproduced
with permission from Devereux et al. (8) Copyrightª 2012, Elsevier Inc.
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2400demonstrated a sex difference in aortic diameter when
corrected for body surface area (BSA) (8). Ascending
aortic dimensions in adults are also related to age, sex,
and BSA (9).
Variability in the measured aortic diameter may result
from the type of imaging modality used, whether contrast
is used, and whether internal or external aortic diameters
are recorded. For example, transthoracic echocardio-
graphic nomograms have reported aortic root diameters
using sinus-to-sinus measurements from a leading-edge
technique at end diastole (10), whereas z-score de-
terminations validated in children have used maximal
end-systolic diameter at the sinuses of Valsalva using in-
ner-edge–to–inner-edge measurements (11). Measure-
ments should be taken perpendicular to the axis of blood
ﬂow and should include the largest measured aortic
diameter (whether at the sinuses of Valsalva or the
ascending aorta) (4). Images taken from echocardiogra-
phy, computed tomography (CT), or magnetic resonance
imaging may overestimate the true aortic diameter if
oblique slices are obtained. CT and magnetic resonance
imaging measurements from sinus to commissure are
generally smaller than echocardiographic measurements
from sinus to sinus (8). CT or magnetic resonance imaging
techniques are used when the extent of aortic enlargement
is not adequately or completely visualized by the echo-
cardiogram. Imaging techniques that avoid or minimize
radiation are recommended whenever possible, particu-
larly when serial assessment is anticipated. Regardless of
which imaging technique is used, it is important that serial
measurements be made at the same location by the same
method for appropriate clinical correlation.
Older nomograms that predict normal and abnormal
aortic dimensions are limited by such factors as failure to
account for sex differences, limited age ranges of subjects
studied (especially teenagers), marked jumps in “normal”
aortic diameter based on age-range strata, and the use of
small sample sizes (8,10).
z Scores
Notably, z scores that incorporate height, weight, age, and
sex are now preferred for determination of normal aortic
diameter as opposed to a single aortic dimension (8). The
z score describes how many standard deviations above
or below a size or age-speciﬁc population mean a given
measurement lies (12). They are especially useful for
evaluation of cardiac dimensions in the young, whose
normal values change during growth.
Aortic dilatation is recognized when the difference
between the observed sinus of Valsalva diameter and the
value predicted for age, sex, and BSA (z score) is >2.0,
which corresponds to approximately the 98th percentile
of the general population (8). A z score of 3 corresponds to
the 99.9th percentile. Mild, moderate, and severe aorticdilatation may be deﬁned by z-score values of 2 to 3, 3.01
to 4.0, and >4.0, respectively (8,13). Reference values
for ascending aortic diameter assessed by echocardiog-
raphy are also available from large databases (14).
A formula for calculating aortic sinus of Valsalva
diameter z scores was derived recently from a data set of
1207 healthy subjects >15 years old, in whom aortic root
diameter ranged from 2.1 to 4.3 cm (8). Aortic dimensions
were calculated by echocardiogram at end diastole from
sinus to sinus using a leading-edge–to–leading-edge
technique (Figure). z Scores are calculated from this
database using the following equation (8) (online-only
Data Supplement aortic z-score calculator):
Expected aortic root size : 2:423þ ðage ½years  0:009Þ
þ ðBSA ½square meters  0:461Þ
 ðsex ½1 ¼ man; 2 ¼ woman  0:267Þ;
standard error of estimate ¼ 0:261 cmz Score ¼ ðobserved aortic root size
expected aortic root sizeÞ=0:261
For example, a 22-year-old man with a BSA of 2.0 m2
has an aortic root diameter of 4.1 cm at the sinuses of
Valsalva. Thus, his expected aortic root size is calculated
as follows:
2:423 þ ð22 0:009Þ þ ð2:0 0:461Þ  0:267 ¼ 3:276
4:1 ðobserved aortic root sizeÞ
 3:28 ðexpected aortic root sizeÞ ¼ 0:824
0:824=0:261 ðstandard error of estimateÞ ¼ 3:16
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for this patient.
AORTIC DIMENSIONS IN ATHLETES
Intense physical exertion is associated with hemody-
namic changes that increase aortic wall tension and may
increase aortic dimension (15–17). Chronic intense weight
training may inﬂuence aortic dimension (18). Further-
more, elite athletes have slightly larger aortas at the
sinuses of Valsalva than nonathletic control subjects (19).
Although mild aortic enlargement may be a normal
adaptation to intense training, large increases in aortic
size are unusual in athletes and when present are more
consistent with an underlying pathological aortopathy,
which may be exacerbated by exercise training (19).
TALL ATHLETES
Although increasing BSA is associated with larger aortic
diameters, there is a nonlinear relationship, with a
plateau, between aortic root dimensions and height
(>189 cm or 74.5 inches in men; >175 cm or 69 inches in
women) and BSA (>2.3 m2) in very tall people (20). A
small proportion of athletes will have an aortic dimen-
sion slightly greater than the diameter considered to
be at the upper limits of normal (i.e., >2 standard de-
viations above the mean, or z score >2) (15,16). There-
fore, it is important to avoid attributing the enlarged
aorta in tall (or large) athletes solely to height, BSA, or
a physiological response to exercise (19). Mild aortic
dilation in an athlete should trigger evaluation to
determine whether an underlying aortopathy is present
and whether the aortic size conveys an increased risk
to the athlete.
We underscore that for athletes with aortic z scores
above the normal range for age, sex, and BSA (i.e.,
z score >2 to 2.5), evaluation by a knowledgeable
specialist, and often by a multidisciplinary team that
includes a medical geneticist and cardiologist, is rec-
ommended to exclude an underlying disorder associated
with aortic dilatation (such as Marfan syndrome, familial
TAA syndrome, or BAV disease). Indeed, systemic fea-
tures of some disorders may be subtle and often overlap
with those in the general population. Referral to a
specialized center with expertise in the clinical and ge-
netic evaluation of genetic aortic disease may be neces-
sary in some instances. In selected cases, we recognize
that it may not be possible to distinguish pathological
aortic dilatation from a nonpathological aortic size when
the aortic measurement mildly exceeds the normal range
in very tall people or in those with large BSA, especially
when there is only a single evaluation at only 1 point
in time.OUTCOME AND RISK OF
AORTIC DISSECTION AND RUPTURE
There is a paucity of data examining the long-term
outcome of athletes with unexplained aortic dilatation
(16,17). Of 2317 Italian athletes, 17 males (ages 25  7
years; height 188  10 cm; BSA 2.17  0.25 m2) had aortic
diameters >40 mm and were allowed to continue
participation (16,17). Over an 8  5 year follow-up, the
aortic root increased mildly in diameter from 40.9  1.3
to 42.9  3.6 mm in these 17 athletes, and none experi-
enced acute aortic dissection. Two athletes had pro-
gressive aortic dilation to 50 mm by ages 38 and
50 years, respectively (17).
The risk of aortic dissection in the general population is
related to many factors, foremost of which is the severity
of aortic dilation, and is sometimes triggered acutely by
heavy weight lifting or strenuous exercise, including
competitive sports (21–22a). However, some patients with
acute aortic dissection do not have a markedly dilated
aorta at the time of dissection (23,24). In a series of 177
patients without the Marfan syndrome phenotype or BAV
who incurred an acute type A dissection, aortic diameter
was <50 mm in 42% and <45 mm in 21% at the time of
dissection. Furthermore, 12% of women had a dissection
at an aortic diameter <40 mm (23). Similarly, in the Inter-
national Registry of Acute Aortic Dissection, 40% of acute
type A dissections occurred with aortic diameters <50 mm
(24). There is no evidence that b-blockers, angiotensin
receptor blockers, or angiotensin-converting enzyme in-
hibitors protect athletes from aortic dissection or rupture
during intense competitive sports.
There are no prospective data available regarding
the risks of competitive athletics in patients who have
undergone surgical correction for aortic aneurysm or
dissection; however, after aortic root replacement, pa-
tients with Marfan syndrome, Loeys-Dietz syndrome, and
familial TAA disease remain at risk for distal aortic com-
plications (3,5,25,26). Additionally, BAV aortopathy may
involve aortic segments distal to the root (27).
PRIOR RECOMMENDATIONS FOR ATHLETES
The 36th Bethesda Conference Report (2005) recom-
mended that athletes with “unequivocal aortic root
enlargement” (therein deﬁned as >40 mm in adults, >2
standard deviations beyond the mean for BSA in children
and adolescents, or a z score of >2) only participate in low-
intensity competitive sports (class IA sports) (28). Char-
acterizing an aortic diameter of >40 mm as enlarged in
males is an arbitrary but also useful deﬁnition, because
very few apparently healthy young male athletes have
been reported with aortic root diameters >40 mm (17,19).
For example, in a study of>2,000 Italian athletes, the 99th
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2402percentile value of aortic diameter by echocardiogram was
40 mm in males and 34 mm in females (16). In a Japanese
study, only 6 of 1,562 male athletes (0.38%) had an aortic
root dimension >40 mm, and 2 of these also had pheno-
typic features of the Marfan syndrome (29). In an evalua-
tion of >1000 female Italian athletes, the 99th percentile
for aortic size at the sinuses of Valsalva was 34 mm, and
no woman had an aortic diameter >36 mm (16,17).
Guidelines for participation in competitive sports have
been lacking for those patients with mildly dilated aortic
dimensions (i.e., z scores of 2 to 2.5, or 1 to 2 mm above
the normal ranges described above) and no diagnosis of
an underlying connective tissue disorder, family history
of aortic disease, or pathogenic gene mutation associated
with aneurysm disease (17). In this situation, there are
difﬁcult individual choices regarding sports participation
to be made on a case-by-case basis. Discussion with the
athlete, parents (when appropriate), and coaches/trainers
should include full disclosure and transparency regarding
the potential risks of further training and competition.
For instance, the mildly dilated aorta may represent a
pathological aortic condition, and the aorta may dilate
further with continued exercise and athletic participa-
tion, or it may dilate years later. In such a person, absence
of a pathogenic genetic mutation does not exclude risk.
Furthermore, although the absolute risk of aortic dissec-
tion or rupture in this clinical situation is unknown, it
is not zero. If participation in competitive sports is
continued, close aortic surveillance (i.e., every 6 to
12 months) with echocardiography or magnetic resonance
angiography (MRA) should be performed to assess aortic
dimension (17). The frequency of imaging is dependent on
the absolute size of the aorta, the z score, stability of the
aortic size, and the intensity of the sport. In the athlete
with a mildly dilated aorta, continued aortic enlargement
should not be regarded as physiological but rather
consistent with an underlying aortopathy; disqualiﬁca-
tion from competition should result if the aorta continues
to enlarge. Because some athletes identiﬁed with only a
mildly dilated aortic root have required aortic aneurysm
surgery several years later, long-term aortic surveillance
is recommended even after engagement in the competi-
tive athletic lifestyle has terminated (17,29).
Recommendations
1. Athletes with Marfan syndrome should undergo
echocardiographic (and in some instances MRA or
CT) measurement of the aortic root dimension every
6 to 12 months, depending on aortic size (Class I;
Level of Evidence C).
2. Athletes with unexplained TAA, familial TAA syn-
drome, or known pathogenic mutation leading to
a familial TAA syndrome (ACTA2, MYH11, FBN1,
TGFBR1, TGFBR2, MLCK, SMAD3, TGFB2, and others)should undergo echocardiographic and (depending
on the diagnosis) MRA or CT surveillance every 6 to
12 months to evaluate for progression of aortic or
branch vessel disease (Class I; Level of Evidence C).
3. Athletes with aortic dimensions mildly above the
normal range (z scores 2 to 2.5 or aortic root dia-
meters measuring 40 to 41 mm in tall men or 36 to
38 mm in tall women) and no features of Marfan
syndrome, Loeys-Dietz syndrome, or familial TAA
syndrome should undergo echocardiographic or MRA
surveillance every 6 to 12 months, with imaging fre-
quency dependent on aortic size and stability of
measurements (Class I; Level of Evidence C).
4. Athletes with BAV can participate in all competitive
athletics if the aortic root and ascending aorta are not
dilated (i.e., z score <2, or <2 standard deviations
from the mean, or <40 mm in adults). The function of
the BAV (whether stenotic or regurgitant) is also
important in determining participation recommen-
dations (see Task Force 5 on valvular heart disease
[30]) (Class I; Level of Evidence C).
5. Athletes with BAV and aortic dimensions above the
normal range (scores 2 to 3 or aortic diameters
measuring 40 to 42 mm in men or 36 to 39 mm in
women) should undergo echocardiographic or MRA
surveillance of the aorta every 12 months, with more
frequent imaging recommended for increasing aortic
z score (Class I; Level of Evidence C).
6. It is reasonable for athletes with Marfan syndrome to
participate in low and moderate static/low dynamic
competitive sports (classes IA and IIA; see deﬁnition
of sports classiﬁcation in Task Force 1 report [31]) if
they do not have ‡1 of the following (Class IIa; Level
of Evidence C):a. Aortic root dilatation (i.e., z score >2, or aortic
diameter >40 mm, or >2 standard deviations from
the mean relative to BSA in children or adoles-
cents <15 years old
b. Moderate to severe mitral regurgitation
c. Left ventricular systolic dysfunction (ejection
fraction <40%)
d. Family history of aortic dissection at an aortic
diameter <50 mm7. It is reasonable for athletes with an unexplained TAA,
familial TAA syndrome, or known pathogenic muta-
tion leading to familial TAA syndrome (ACTA2,MYH11,
FBN1, TGFBR1, TGFBR2, MLCK, SMAD3, TGFB2, and
others) to participate in low static, low dynamic
competitive sports (class IA) if they do not have ‡1
of the following (Class IIa; Level of Evidence C):a. Aortic root dilatation (i.e., score >2, or aortic
diameter >40 mm, or >2 standard deviations from
the mean relative to BSA for children and adoles-
cents <15 years old)
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c. Family history of aortic dissection
d. Cerebrovascular disease
e. Branch vessel aneurysm or dissection8. It is reasonable for athletes with Loeys-Dietz syn-
drome or vascular Ehlers-Danlos syndrome to
participate in low static, low dynamic sports (class IA)
if they do not have any of the following (Class IIa;
Level of Evidence C):a. Aortic enlargement (score >2) or dissection, or
branch vessel enlargement
b. Moderate to severe mitral regurgitation
c. Extracardiac organ system involvement that
makes participation hazardous9. It is reasonable for athletes with surgical correction
of the aortic root or ascending aorta for aneurysm
disease or dissection and no evidence of residual
aortic enlargement or dissection to participate in low
static, low dynamic sports (class IA) that do not
include the potential for bodily collision (Class IIa;
Level of evidence C).
10. For athletes with a BAV and a mild to moderately
dilated aorta (score 2 to 3.5 or aortic root or
ascending aortic diameters measuring 40 to 42 mm in
men or 36 to 39 mm in women) and no features of
associated connective tissue disorder or familial TAA
syndrome, participation in low and moderate static
and dynamic competitive sports with a low likeli-
hood of signiﬁcant bodily contact (classes IA, IB, IC,
IIA, IIB, and IIC) may be considered. For these ath-
letes, avoidance of intense weight training should be
considered (Class IIb; Level of Evidence C).
11. For athletes with aortic dimensions mildly above the
normal range (scores 2 to 2.5 or aortic root diameters
measuring 40 to 41 mm in tall men or 35 to 37 mm in
tall women) and no features of Marfan syndrome,
Loeys-Dietz syndrome, familial TAA syndrome, or
BAV, participation in all competitive athletics may beconsidered after a comprehensive evaluation for an
underlying genetic condition associated with aort-
opathy is performed. This may include analysis for
mutations in FBN1 and other genes associated with
aortopathies in certain circumstances (Class IIb;
Level of Evidence C).
12. For athletes with aortic dimensions mildly above
the normal range (scores 2 to 2.5 or aortic root di-
ameters measuring 40 to 41 mm in tall men or 35 to
37 mm in tall women) and no features of Marfan
syndrome, Loeys-Dietz syndrome, familial TAA
syndrome, or BAV, avoidance of intense weight
training may be considered (Class IIb; Level of
Evidence C).
13. For athletes with a BAV and a dilated aorta
measuring 43 to 45 mm, participation in low-
intensity competitive sports (class IA) with a low
likelihood of bodily contact may be considered
(Class IIb; Level of Evidence C).
14. Athletes with Marfan syndrome, familial TAA syn-
drome, Loeys-Dietz syndrome, unexplained aortic
aneurysm, vascular Ehlers-Danlos syndrome, or a
related aortic aneurysm disorder should not partici-
pate in any competitive sports that involve intense
physical exertion or the potential for bodily collision
(Class III; Level of Evidence C).
15. Athletes with BAV and a severely dilated aorta (score
>3.5 to 4 or >43 mm in men or >40 mm in women)
should not participate in any competitive sports that
involve the potential for bodily collision (Class III;
Level of Evidence C).
16. Athletes with BAV and a markedly dilated aorta (>45
mm) should not participate in any competitive sports
(Class III; Level of Evidence C).
17. Athletes with chronic aortic dissection or branch
vessel arterial aneurysm or dissection should not
participate in any competitive sports (Class III; Level
of Evidence C).
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